Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, Montaudon E, Beerenwinkel N, Kruithof-de Julio M, Terracciano LM, Lengerke C, Jeselsohn RM, Doebele RC, Bidard FC, Marangoni E, Ng CKY, Piscuoglio S. Bianco G, et al. Among authors: de menna m. Commun Biol. 2022 Apr 19;5(1):373. doi: 10.1038/s42003-022-03296-x. Commun Biol. 2022. PMID: 35440675 Free PMC article.
Metastases in Prostate Cancer.
Manna F, Karkampouna S, Zoni E, De Menna M, Hensel J, Thalmann GN, Kruithof-de Julio M. Manna F, et al. Among authors: de menna m. Cold Spring Harb Perspect Med. 2019 Mar 1;9(3):a033688. doi: 10.1101/cshperspect.a033688. Cold Spring Harb Perspect Med. 2019. PMID: 29661810 Free PMC article. Review.
A NF-ĸB-Activin A signaling axis enhances prostate cancer metastasis.
Chen L, De Menna M, Groenewoud A, Thalmann GN, Kruithof-de Julio M, Snaar-Jagalska BE. Chen L, et al. Among authors: de menna m. Oncogene. 2020 Feb;39(8):1634-1651. doi: 10.1038/s41388-019-1103-0. Epub 2019 Nov 18. Oncogene. 2020. PMID: 31740783
Patient-derived xenografts and organoids model therapy response in prostate cancer.
Karkampouna S, La Manna F, Benjak A, Kiener M, De Menna M, Zoni E, Grosjean J, Klima I, Garofoli A, Bolis M, Vallerga A, Theurillat JP, De Filippo MR, Genitsch V, Keller D, Booij TH, Stirnimann CU, Eng K, Sboner A, Ng CKY, Piscuoglio S, Gray PC, Spahn M, Rubin MA, Thalmann GN, Kruithof-de Julio M. Karkampouna S, et al. Among authors: de menna m. Nat Commun. 2021 Feb 18;12(1):1117. doi: 10.1038/s41467-021-21300-6. Nat Commun. 2021. PMID: 33602919 Free PMC article.
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, Tirunagaru VG, De Menna M, Paradiso V, Ercan C, Dahmani A, Montaudon E, Beerenwinkel N, Kruithof-de Julio M, Terracciano LM, Lengerke C, Jeselsohn RM, Doebele RC, Bidard FC, Marangoni E, Ng CKY, Piscuoglio S. Bianco G, et al. Among authors: de menna m. Commun Biol. 2022 Jul 4;5(1):658. doi: 10.1038/s42003-022-03612-5. Commun Biol. 2022. PMID: 35787660 Free PMC article. No abstract available.
A model for network-based identification and pharmacological targeting of aberrant, replication-permissive transcriptional programs induced by viral infection.
Laise P, Stanifer ML, Bosker G, Sun X, Triana S, Doldan P, La Manna F, De Menna M, Realubit RB, Pampou S, Karan C, Alexandrov T, Kruithof-de Julio M, Califano A, Boulant S, Alvarez MJ. Laise P, et al. Among authors: de menna m. Commun Biol. 2022 Jul 19;5(1):714. doi: 10.1038/s42003-022-03663-8. Commun Biol. 2022. PMID: 35854100 Free PMC article.
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
Seiler R, Egger M, De Menna M, Wehrli S, Minoli M, Radić M, Lyatoshinsky P, Hösli R, Blarer J, Abt D, Kruithof-de Julio M. Seiler R, et al. Among authors: de menna m. BMC Urol. 2023 May 11;23(1):89. doi: 10.1186/s12894-023-01262-1. BMC Urol. 2023. PMID: 37170307 Free PMC article. Clinical Trial.
Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.
La Manna F, De Menna M, Patel N, Karkampouna S, De Filippo MR, Klima I, Kloen P, Beimers L, Thalmann GN, Pelger RCM, Jacinto E, Kruithof-de Julio M. La Manna F, et al. Among authors: de menna m. Front Oncol. 2021 Feb 3;11:650623. doi: 10.3389/fonc.2021.650623. eCollection 2021. Front Oncol. 2021. PMID: 33614519 Free PMC article.
20 results